J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More

Daily round-up of news and notes from the 2017 J.P. Morgan Healthcare conference in San Francisco. Bristol-Myers CEO humbled by PD-1 competition in lung cancer; Sanofi’s sarilumab manufacturing issues resolved; Biogen, Ionis discuss SMA drug’s high cost; Shire happy with Xiidra launch to date; Sarepta says more than 250 patients have started Exondys treatment; J&J’s Gorsky on innovation and pricing; and Amicus reveals US approval strategy for migalastat.

Bristol-Myers Squibb Co. CEO Giovanni Caforio took the stage at the J.P. Morgan Healthcare Conference on Jan. 10 humbled by a clinical trial disappointment and increased competition for the company’s PD-1 inhibitor Opdivo (nivolumab), but he was hopeful about building and maintaining a strong market share across Bristol’s immuno-oncology platform. (Also see "Does CheckMate 026 Take Bristol Out Of The End Game?" - Scrip, 6 August, 2016.)

The surprising failure of the Checkmate-026 clinical trial testing Opdivo versus chemotherapy in first-line lung cancer opened a huge opportunity...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip